|Purdue University researchers have synthesized kinase inhibitors that display potent anti-proliferative effects when dosed into lung, pancreatic, and colon cancer cells. Overactive kinases are a primary driver of cancer cell proliferation. Accordingly, many chemotherapeutic regimens contain kinase inhibitors; however, current kinase targeting compounds are not effective in treating aggressive forms of lung, pancreatic, and colon cancers. Purdue University researchers have optimized previously identified kinase inhibitors to achieve a higher potency against many lung, pancreatic, and colon cancer cell lines. These compounds were tested against the NCI-60 cancer cell panel and have low sub micromolar GI50 values. For example, the GI50 against some colon cancers are as low as 5 nM. These compounds also have IC50 values of 25 nM against proliferation of the MiaPaCa-2 pancreatic cancer cell line. The potency of the compounds toward multiple aggressive cancer cell lines makes them promising cancer therapeutic candidates for future development.
Technology Validation: The compounds were tested against the NCI-60 cancer cell line panel and exhibit nanomolar GI50 values in some cell lines.
-Inhibits Growth of Multiple Cancer Cell Lines
-Increased Potency versus Previously Identified Molecules
Jun 24, 2020
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486